Drug Development Linked More Closely to Diagnostics

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-10-02-2004, Volume 28, Issue 10

FDA and industry discuss proposals for regulating combination diagnostics, medical devices, and pharmacogenomic-based drug products.

Related Content:

FormulationProcess ValidationQuality SystemsRegulatory WatchDevelopmentPharmaceutical Technology-10-02-2004
Susan Schniepp of Regulatory Compliance Associates Explores the Impact of QMS on Quality Maturity (INTERPHEX 2024)
Keynote Session Highlights Importance of Process Validation and Data Integrity (INTERPHEX 2024)
FDA Establishes Center for Clinical Trial Innovation